Mer­ck’s can­cer R&D jug­ger­naut ties up to lit­tle Drag­on­fly’s nat­ur­al born killer plat­form — with bil­lions on the line

A lit­tle more than a year af­ter Cel­gene bel­lied up to the part­ner­ship ta­ble with $33 mil­lion in cash to al­ly it­self with the up­start crew at Drag­on­fly, Mer­ck has now fol­lowed be­hind in search of what they’re hop­ing is a game-chang­ing ap­proach to treat­ing sol­id tu­mors.

“There’s no com­pa­ny that knows sol­id tu­mors more than Mer­ck,” says Drag­on­fly CEO Bill Haney, who re­cent­ly jumped in­to biotech with a pair of new com­pa­nies look­ing to make their mark in dif­fer­ent fields.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER